Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

532
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
532
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

391
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
391
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

603
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
603
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

354
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
354
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

376
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
376
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

942
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
942

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Gastrointestinal infections in pediatric populations.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Cost-effectiveness of Microbiota Restoration Therapies for Recurrent Clostridioides difficile Infection.

The American journal of gastroenterology·2026
Same author

When Does Clostridioides difficile "Recur"? Reconcile Epidemiologic & Bedside Recurrent CDI definitions.

The Journal of infectious diseases·2026
Same author

Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.

Infectious diseases and therapy·2026
Same author

Clostridioides difficile infection in inflammatory bowel disease: an observational study in flares of ulcerative colitis and a South Asian region-specific systematic review and meta-analysis.

Therapeutic advances in gastroenterology·2026
Same author

AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review.

Gastroenterology·2026

Related Experiment Video

Updated: Dec 25, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K

Update on Treatment of Clostridioides difficile Infection.

Janice M Cho1, Darrell S Pardi2, Sahil Khanna2

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|April 6, 2020
PubMed
Summary

Clostridioides difficile infection (CDI) is a major healthcare concern. This review covers current and emerging Clostridioides difficile treatments and updated therapy guidelines.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.7K

Related Experiment Videos

Last Updated: Dec 25, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.7K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Gastroenterology

Background:

  • Clostridioides difficile infection (CDI) is a primary cause of healthcare-associated infections in the U.S.
  • Rising CDI incidence and recurrence rates are significant concerns due to associated morbidity and mortality.
  • Emerging treatments aim to address the limitations of existing therapies.

Purpose of the Study:

  • To review the current standard of care for Clostridioides difficile infection (CDI).
  • To summarize emerging therapeutic strategies for CDI.
  • To present updated treatment guidelines for CDI.

Main Methods:

  • A comprehensive literature search of PubMed was conducted for studies published between 2010 and 2018.
  • Keywords used included "Clostridium difficile," "treatment," and "therapy."
  • Cited references were also reviewed to identify relevant literature.

Main Results:

  • The review synthesizes information on established and novel CDI treatments.
  • It highlights advancements in narrow-spectrum antibiotics, monoclonal antibodies, and microbial replacement therapies.
  • Updated clinical guidelines for CDI management are summarized.

Conclusions:

  • Effective management of Clostridioides difficile infection (CDI) requires understanding both standard and novel therapeutic options.
  • The landscape of CDI treatment is evolving with the introduction of targeted therapies.
  • Adherence to updated guidelines is crucial for optimizing patient outcomes.